Keysha Brooks-Coley Discusses Project to Address Health Equity and Disparities for Minority Patients

Video

The American Cancer Society Cancer Action Network partnered with the National Comprehensive Cancer Network and the National Minority Quality Forum to produce recommendations addressing issues regarding health equity and disparities among minority patients with cancer.

CancerNetwork® recently spoke with Keysha Brooks-Coley, vice president for federal advocacy and strategic alliances at the American Cancer Society Cancer Action Network (ACS CAN), regarding the Elevating Cancer Equity Project.

The project is a collaboration with the National Comprehensive Cancer Network (NCCN) and the National Minority Quality Forum (NMQF), focusing on addressing health equity and health disparity issues in minority communities.

“We know that minority communities often times don’t have access to coverage, don’t have access to life-saving screenings, prevention, and access to treatment because of insurance status, for example,” explained Coley-Brooks. “We have been working on many of those issues for many, many years and continue to [do so]. Last year we saw an opportunity to work with other partner organizations and really lean in even more on health disparities and looking at guideline-adherent care for individuals of diverse backgrounds.”

ACS CAN is the advocacy arm of the American Cancer Society, which works to prevent cancer, seek new treatments and cures for cancer, and ensure all patients have access to quality life-saving cancer care.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

Recent Videos
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
The Together for Supportive Cancer Care coalition may advance the national conversation in ensuring comprehensive care for all patients with cancer.
Health care organizations have come together to form the Together for Supportive Cancer Care coalition to address gaps in supportive cancer care services.
Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.